◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Heidelberg Pharma AG (HPHA) Financial History

Name: Heidelberg Pharma AG (HPHA) financial statement history
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-11-04

Heidelberg Pharma AG (HPHA) operates in the Biotechnology industry and is headquartered in Ladenburg, Germany with about 33 employees. Its market capitalization is roughly €97 million. In the fiscal year ended 2025-11-30, HPHA reported €2M in revenue and (€42M) in net income.

Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, Europe, China, the United States, and internationally.

Interactive charts & full statements → Open the HPHA valuation workbench →

HPHA Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-08-31	2025-11-30	2024-11-30	2023-11-30	2022-11-30
Total Revenue	€9M	€2M	€7M	€10M	€18M
Gross Profit	€8M	€1M	€5M	€7M	€14M
Operating Income (EBIT)	(€29M)	(€42M)	(€21M)	(€21M)	(€17M)
Net Income	(€30M)	(€42M)	(€19M)	(€20M)	(€20M)

EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

HPHA Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-08-31	2026-05-31	2026-02-28	2025-11-30	2025-05-31	2025-02-28
Total Revenue	€2M	€4M	€3M	€0M	€0M	—
Gross Profit	€1M	€4M	€3M	(€0M)	€0M	—
Operating Income (EBIT)	(€5M)	€1M	(€4M)	(€20M)	(€7M)	—
Net Income	(€5M)	€1M	(€4M)	(€21M)	(€7M)	—

EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

HPHA Free Cash Flow History

HPHA Balance Sheet History

Balance sheet	2025-11-30	2024-11-30	2023-11-30	2022-11-30	2021-11-30
Total Assets	€38M	€61M	€70M	€101M	—
Total Liabilities	€49M	€30M	€21M	€34M	—

EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive HPHA viewer.

Other Companies in Biotechnology

ENGN · enGene Therapeutics Inc. — $105 million
GNLX · Genelux Corporation — $100 million
ATRA · Atara Biotherapeutics, Inc. — $99 million
ONCY · Oncolytics Biotech Inc. — $98 million
ICCC · ImmuCell Corporation — $96 million
INO · Inovio Pharmaceuticals, Inc. — $96 million
ANIX · Anixa Biosciences, Inc. — $96 million
NTHI · NeOnc Technologies Holdings, Inc. — $95 million

← HPF All “H” companies HPIL →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.